NCT02497157 Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT02489916 Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02476045 Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) Status UNKNOWN Phase PHASE2
NCT02469480 Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. Status COMPLETED Phase PHASE2
NCT02453464 A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer Status UNKNOWN Phase PHASE1
NCT02448810 Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer Status TERMINATED Phase PHASE2
NCT02437071 Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Status COMPLETED Phase PHASE2
NCT02414009 Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Status COMPLETED Phase PHASE2
NCT02404935 Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) Status COMPLETED Phase PHASE2
NCT02364024 Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas Status COMPLETED Phase N/A
NCT02350530 FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type Status COMPLETED Phase PHASE2
NCT02345746 Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis Status WITHDRAWN Phase PHASE2
NCT02339116 Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC Status UNKNOWN Phase PHASE3
NCT02332499 Study of Anlotinib in Patients With Metastatic Colorectal Cancer(mCRC)(ALTER0703) Status COMPLETED Phase PHASE2/PHASE3
NCT02331927 PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer Status UNKNOWN Phase PHASE2
NCT02322736 Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR Status COMPLETED Phase N/A
NCT02310477 Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting Status COMPLETED Phase N/A
NCT02310464 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Status COMPLETED Phase PHASE1